- Biotech has been the worst performing sector of the stock market across the past 12 months.
- That seems improbable given e.g. the discovery of MRNA vaccines, breakthroughs in gene therapy etc. But the hype cycle hit its peak in 2021 with too many big-money IPOs.
- The sector is down ~45% from March 2021 highs and it's hard to say if the market is anywhere close to reaching its bottom.
- Investors shouldn't be fooled by the glamour of drug discovery, should do their due diligence, and be pragmatic. Identifying and understanding catalysts is an essential part of the process.
- In this post I update on three biotech concerns - Iveric Bio, Liquidia Corp and Sensus Healthcare - whose share prices have bucked the trend and are +100% over the past year.
For further details see:
Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear Market